Growth hormone binding protein and acid labile subunit levels in the assessment of acromegaly treatment.

Objective: Post-treatment monitoring of acromegalic patients is a matter of controversy, as discrepancies between GH and IGF-I levels have been reported. The aim of our study was to evaluate the role of acid-labile subunit (ALS), a component of the 150 kD IGF-I/IGFBP-3/ALS complex, and the growth hormone binding protein (GHBP) in the follow-up of patients with acromegaly after therapeutic intervention.

Design: Forty-one patients with acromegaly, 10 at the time of diagnosis and 31 post therapeutic intervention, were studied.